Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharvaris NVPHVS +2.68%22 Equity-to-Asset is 0.92 as of Jun. 2026, which is at its 10-year median of 0.92. GuruFocus rates PHVS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,414 Biotechnology companies, Pharvaris NV ranks better than 88.26% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Pharvaris NV's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $346.56 Mil. Pharvaris NV's Total Assets for the quarter that ended in Jun. 2026 was $378.65 Mil.
The historical rank and industry rank for Pharvaris NV's Equity-to-Asset or its related term are showing as below:
PHVS'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.87 Med: 0.92 Max: 0.97
Current: 0.92
During the past 9 years, the highest Equity to Asset Ratio of Pharvaris NV was 0.97. The lowest was 0.87. And the median was 0.92.
PHVS's Equity-to-Asset is ranked better than 88.26% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs PHVS: 0.92
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Pharvaris NV Equity-to-Asset Related Terms
Pharvaris NV Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Pharvaris NV's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHVS vs PGEN, NKTR, VERA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Pharvaris NV's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharvaris NV Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharvaris NV's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Pharvaris NV's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Pharvaris NV's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharvaris NV (PHVS) has a Equity-to-Asset of 0.92 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Pharvaris NV and its competitors. This is near median its historical median of 0.92. Over the past decade, Pharvaris NV's Equity-to-Asset has ranged from 0.87 to 0.97. According to the industry distribution chart, Pharvaris NV ranks #166 out of 1414 companies in the Biotechnology industry, placing it in the top 11.7%.
Is Pharvaris NV's Equity-to-Asset too high?
Pharvaris NV's current Equity-to-Asset of 0.92 is near median its 10-year median of 0.92. Over the past 10 years, this metric has ranged from a low of 0.87 to a high of 0.97. The Biotechnology industry median Equity-to-Asset is 0.68. Pharvaris NV's value of 0.92 is 35.3% above this industry median. Based on the distribution chart, Pharvaris NV ranks #166 out of 1414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharvaris NV has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's Equity-to-Asset compare to PGEN and NKTR?
According to the Biotechnology industry distribution chart, Pharvaris NV ranks #166 out of 1414 companies for Equity-to-Asset. This places Pharvaris NV in the top 12% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Pharvaris NV's value of 0.92 is 35.3% above this benchmark. Historically, Pharvaris NV's own Equity-to-Asset has ranged from 0.87 to 0.97 over the past decade. While the company's 10-year median is 0.92 vs. the industry median of 0.68, Pharvaris NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharvaris NV's current Equity-to-Asset of 0.92 is 35.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Pharvaris NV and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharvaris NV's current Equity-to-Asset is 0.92, which is near median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (PHVS) has a current Equity-to-Asset of 0.92. The current Equity-to-Asset is 0.92, which is near median its 10-year median of 0.92 and 35.3% above the Biotechnology industry median of 0.68. Pharvaris NV's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Pharvaris NV (PHVS), the current Equity-to-Asset is 0.92 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
22GF Score
Get the complete analysis for PHVS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHVS has been successfully added to your 
